8.79
0.18 (2.09%)
| Penutupan Terdahulu | 8.61 |
| Buka | 8.95 |
| Jumlah Dagangan | 909,424 |
| Purata Dagangan (3B) | 523,462 |
| Modal Pasaran | 162,204,512 |
| Harga / Pendapatan (P/E Ke hadapan) | 21.51 |
| Harga / Jualan (P/S) | 1.66 |
| Harga / Buku (P/B) | 1.32 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 May 2025 - 16 May 2025 |
| Margin Keuntungan | -21.83% |
| Margin Operasi (TTM) | 11.24% |
| EPS Cair (TTM) | -1.10 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 13.90% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 28.37% |
| Nisbah Semasa (MRQ) | 2.89 |
| Aliran Tunai Operasi (OCF TTM) | 4.89 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 9.40 M |
| Pulangan Atas Aset (ROA TTM) | -2.19% |
| Pulangan Atas Ekuiti (ROE TTM) | -16.51% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Health Information Services (US) | Menurun | Bercampur |
| Health Information Services (Global) | Menurun | Bercampur | |
| Stok | OptimizeRx Corporation | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 4.0 |
| Purata | 1.25 |
|
OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its products offering are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement. |
|
| Sektor | Healthcare |
| Industri | Health Information Services |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 6.41% |
| % Dimiliki oleh Institusi | 65.38% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 14.00 (JMP Securities, 59.27%) | Beli |
| Median | 13.25 (50.74%) | |
| Rendah | 12.50 (Stifel, 42.21%) | Beli |
| Purata | 13.25 (50.74%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 11.01 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| JMP Securities | 13 May 2025 | 14.00 (59.27%) | Beli | 11.01 |
| Stifel | 13 May 2025 | 12.50 (42.21%) | Beli | 11.01 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 16 May 2025 | Pengumuman | OptimizeRx to Participate in Upcoming Investor Conferences |
| 12 May 2025 | Pengumuman | OptimizeRx Reports First Quarter 2025 Financial Results and Updates Fiscal Year 2025 Guidance |
| 01 May 2025 | Pengumuman | OptimizeRx Releases 2025 Environmental, Social, and Governance (ESG) Report |
| 23 Apr 2025 | Pengumuman | OptimizeRx Sets First Quarter 2025 Conference Call for May 12, 2025, at 4:30 p.m. ET |
| 18 Apr 2025 | Pengumuman | OptimizeRx Corporation Announces Plan for Additional Board of Directors Refreshment |
| 12 Mar 2025 | Pengumuman | OptimizeRx Reports Strong Fourth Quarter and Full Year 2024 Financial Results |
| 11 Mar 2025 | Pengumuman | OptimizeRx Corporation Confirms Receipt of Notice of Director Nominations |
| 10 Mar 2025 | Pengumuman | OptimizeRx Corporation Appoints Stephen Silvestro as Chief Executive Officer |
| 27 Feb 2025 | Pengumuman | OptimizeRx Sets Fourth Quarter and Full Year 2024 Financial Results Conference Call for March 12, 2025, at 8:30 a.m. ET |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |